What is the purpose of a 10-Q filing?

A 10-Q filing is a comprehensive report of a company's financial performance that is required by the U.S. Securities and Exchange Commission (SEC) to be filed quarterly. It provides investors with an update on the company's financial condition, including financial statements and management's discussion and analysis of financial results and condition.

Where can I find the actual financial numbers for Abbott Laboratories from this filing?

The provided text is an excerpt of the SEC filing's directory listing and navigation. To find the detailed financial statements (income statement, balance sheet, cash flow statement) and management discussion, you would need to access the full filing document, typically available in .txt or .html format, through the SEC's EDGAR database or other financial data providers.

What would an investor typically look for in this 1995 10-Q filing?

An investor would typically look for key financial metrics such as revenue growth, net income, earnings per share, profit margins, and changes in assets and liabilities. They would also review the Management's Discussion and Analysis (MD&A) section for insights into the company's performance drivers, risks, and future outlook during that specific quarter in 1995.

Does this filing indicate any specific positive or negative news for Abbott Laboratories?

The provided excerpt does not contain specific financial results or narrative from Abbott Laboratories' management. Therefore, it is not possible to determine from this text alone whether the filing indicates positive or negative news. A review of the full 10-Q document would be necessary to assess the company's performance and any associated commentary.

ABT 10-Q Quarterly Report Q3 FY1995 — Revenue, Net Income, EPS

Summary

Abbott Laboratories' third-quarter 1995 10-Q filing indicates a company navigating its financial performance during a dynamic period. While specific financial figures for revenue, profit, and balance sheet items are not detailed in the provided excerpt, the filing's existence signals ongoing operational activity and regulatory compliance. Investors would typically look for trends in sales growth, profitability margins, and any significant changes in assets or liabilities to assess the company's health and future prospects. Investors should focus on how Abbott Laboratories is managing its product lines, market competition, and any potential impacts from broader economic conditions in the mid-1990s. Key areas of interest would include any disclosed strategic initiatives, research and development investments, or significant acquisitions/divestitures that could shape future earnings. The absence of detailed financial tables in this excerpt means further investigation into the full filing is crucial for a comprehensive understanding of the company's financial standing.

Key Highlights

1Abbott Laboratories filed a Quarterly Report (10-Q) for the period ending September 29, 1995.
2The filing was made with the SEC on November 13, 1995.
3This report provides an update on the company's financial status for the third quarter of 1995.
4The provided text is primarily navigational and structural for the SEC EDGAR database, not the detailed financial content of the 10-Q.
5Investors would need to access the full .txt or .html filing for detailed financial statements and management discussion.
6The filing confirms Abbott Laboratories' continued operation and reporting obligations during this period.

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 1995

Summary

Key Highlights

Frequently Asked Questions